30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

3Q14 Revenue: Globus Medical

$117.8MM, +10% (U.S. +9%, ex-U.S. +23%)

  • Innovative Fusion $67.7MM, +8%
  • Disruptive Technologies $50.1MM, +12%


  • Expanded rollout of CREO next-gen pedicle screw platform, launched SILC low-profile sublaminar fixation system, commenced launch of Altera articulating expandable TLIF spacer
  • Price pressure in mid-single-digits, consistent with prior quarter
  • No direct impact from media coverage of PODs, but hopeful that scrutiny will support avoiding them
  • Acquired Transplant Technologies of Texas (TTOT), allograft tissue processor/manufacturer, for $35MM up front and $15MM in potential milestone payments
  • TTOT products include SteriSorb Sponge, 100% cancellous compressible sponge; SteriShield Amnion Patch for wound protection and SteriFlex Wrap, 100% cortical sheet that can be bent, contoured or rolled
  • TTOT supports future products such as precision machined spacers, next-gen DBMs and specialty products
  • Could see biologics at 10% to 15% of revenue over a 3 to 4 year period
  • Still on track for 2016 robotics project from Excelsius acquisition